N-Terminal scFv Multispecific Binding Molecules for Cancer
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current antibody therapies often suffer from reduced target specificity, leading to off-target effects, particularly in immunotherapy contexts. Additionally, single antibodies may not be effective in treating diseases that require targeting multiple antigens or epitopes.
Innovation Solution
The development of multispecific binding molecules (MBMs) that contain at least three antigen-binding sites, including two Fabs and an scFv attached to one of the Fabs, to enhance target specificity and therapeutic efficacy by simultaneously binding to multiple targets.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If single antibodies are used for treatment, then the treatment is simple and targeted, but the target specificity is reduced leading to off-target effects
Solution Approach 1:
The patent applies multi-functionality by designing multispecific antibodies that can bind to multiple different antigens simultaneously. Each antibody molecule is engineered to possess multiple antigen-binding sites with different specificities, allowing a single therapeutic agent to target multiple disease-relevant antigens and reduce off-target effects through synergistic binding
2Adaptability or versatility
If antibodies targeting multiple antigens are developed, then therapeutic control is improved, but the molecular complexity increases
Solution Approach 1:
The patent employs segmentation by dividing the antibody structure into modular domains including variable regions (VH, VL) and constant regions (CH1, CL, Fc). Each domain can be independently designed and assembled to create multispecific antibodies with controlled complexity, where different antigen-binding specificities are distributed across separate modular units
Solution Approach 2:
The patent applies nesting by incorporating scFv (single-chain variable fragment) structures within the larger antibody framework. The scFv domains are nested between the Fab regions and Fc regions, creating a hierarchical structure where multiple antigen-binding specificities are integrated into a unified molecular architecture
Data Source
AI summary
Multispecific binding molecules (MBMs) comprising an N-terminal scFv, a first Fab and a second Fab, MBM conjugates comprising the MBMs and cytotoxic or cytostatic agents, pharmaceutical compositions containing the MBMs and MBM conjugates, methods of using the MBMs, MBM conjugates and pharmaceutical compositions for treating cancer, nucleic acids encoding the MBMs, cells engineered to express the MBMs, and methods of producing MBMs.